Discovery of 4-(2-(methylamino)thiazol-5-yl)pyrimidin-2-amine derivatives as novel cyclin-dependent kinase 12 (CDK12) inhibitors for the treatment of esophageal squamous cell carcinoma
Bioorganic Chemistry · 2025
DOI: 10.1016/j.bioorg.2025.108302 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2025. Verfasst von Yin Cao und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Cellular Stress Biology and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sci…. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Cyclin-Dependent Kinases, Esophageal Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Fujian Provincial Natural Science Foundation, Hubei Province Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
The transcriptional cyclin-dependent protein kinase 12 (CDK12), a potential target in various cancers, was recently discovered with a dramatic amplification in esophageal cancer (EC). In this study, we conducted an online database analysis that revealed CDK12 to be overexpressed in esophageal squamous cell carcinoma (ESCC) tissue samples from patients. Furthermore, survival analysis indicated that CDK12 can serve as a prognostic indicator for ESCC patients. In addition, CDK12 knockdown had been shown to reduce the proliferation of ESCC cells. The present study also details the design, synthesis, and biological evaluation of new CDK12 inhibitors which bear the scaffold of 4-(2-(methylamino)thiazol-5-yl)pyrimidin-2-amine. Among the synthesized compounds, H63 has been identified as a potent inhibitor of CDK12 with excellent anti-ESCC activity. Mechanistically, H63 blocked transcription elongation, downregulated the G1-phase core genes to induce cell cycle arrest, and altered the CDK12-ATM/ATR-CHEK1/CHEK2 signaling axis to cause DNA damage. In addition, H63 exhibited favorable pharmacokinetic properties, good safety, and prominent anti-ESCC activity in vivo. The present study suggests that CDK12 is a promising target for ESCC treatment, and H63 is a promising candidate for further clinical development as an anti-ESCC drug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Cellular Stress Biology and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.
- State Key Laboratory of Cellular Stress Biology and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China; MOE Key Lab of Rare Pe…
- State Key Laboratory of Cellular Stress Biology and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China; Technical Innovation C…
- State Key Laboratory of Cellular Stress Biology and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China; School of Traditional…
- State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen 361102, China.
- State Key Laboratory of Cellular Stress Biology and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China; School of Pharmacy, Hu…
Förderung
- Fujian Provincial Natural Science Foundation
- Hubei Province Natural Science Foundation
- National Natural Science Foundation of China
- Natural Science Foundation of Xiamen Municipality
- Xiamen University
- Natural Science Foundation of Hebei Province
Zitieren
APA
Cao, Y., Huang, S., He, Y., Zhang, Y., Chen, S., Huang, M., He, F., Chen, S., Wang, D., Yang, Z., Zhao, X., Wang, X., Wu, Z., Ao, M., Qiu, Y., & Fang, M. (2025). Discovery of 4-(2-(methylamino)thiazol-5-yl)pyrimidin-2-amine derivatives as novel cyclin-dependent kinase 12 (CDK12) inhibitors for the treatment of esophageal squamous cell carcinoma. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.108302
Vancouver
Cao Y, Huang S, He Y, Zhang Y, Chen S, Huang M, et al. Discovery of 4-(2-(methylamino)thiazol-5-yl)pyrimidin-2-amine derivatives as novel cyclin-dependent kinase 12 (CDK12) inhibitors for the treatment of esophageal squamous cell carcinoma. Bioorganic Chemistry. 2025. doi:10.1016/j.bioorg.2025.108302
BibTeX
@article{Cao2025,
author = {Cao, Yin and Huang, Sen and He, Yaohui and Zhang, Yuxiang and Chen, Simian and Huang, Mengxian and He, Fengming and Chen, Shutong and Wang, Di and Yang, Ziying and Zhao, Xinwei and Wang, Xiumin and Wu, Zhen and Ao, Mingtao and Qiu, Yingkun and Fang, Meijuan},
title = {Discovery of 4-(2-(methylamino)thiazol-5-yl)pyrimidin-2-amine derivatives as novel cyclin-dependent kinase 12 (CDK12) inhibitors for the treatment of esophageal squamous cell carcinoma},
journal = {Bioorganic Chemistry},
year = {2025},
doi = {10.1016/j.bioorg.2025.108302}
}
EUVIMED